Zealand Pharma CEO to Discuss Metabolic Health Strategy at Morgan Stanley Conference
Event summary
- Zealand Pharma CEO Adam Steensberg to participate in fireside chat at Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026.
- Live audio webcast available via Zealand Pharma's investor relations page.
- Company focuses on obesity and metabolic health with 10 drug candidates in clinical development.
- Two Zealand Pharma products have reached market, three in late-stage development.
- Collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
The big picture
Zealand Pharma's participation in the Morgan Stanley conference underscores its focus on advancing metabolic health solutions amid a competitive biotech landscape. The company's emphasis on AI/ML-driven R&D and strategic collaborations positions it to capitalize on the growing demand for obesity treatments. With multiple drug candidates in development, Zealand Pharma aims to solidify its role as a key player in the metabolic health sector.
What we're watching
- Pipeline Progress
- How Zealand Pharma's late-stage drug candidates will impact its market position in obesity and metabolic health.
- Strategic Collaborations
- Whether the company's partnerships will accelerate commercialization of its drug candidates.
- Market Dynamics
- The pace at which Zealand Pharma can scale its proprietary data platform to drive innovation in metabolic health.
Related topics